FDA Review of Varenicline and Risk of Cardiovascular Adverse Events

DECEMBER 19, 2012
This podcast, from the Centers for Disease Control and Prevention, discusses a drug safety communication released by the FDA on December 12, 2012, regarding the risk of cardiovascular adverse events associated with the smoking-cessation drug varenicline (Chantix).
 
To download the podcast, click here.

SHARE THIS SHARE THIS
0
Pharmacy Times Strategic Alliance
 

Pharmacist Education
Clinical features with downloadable PDFs

SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.